WFH Twinning Program partnerships around the world have improved diagnosis and treatment, enriched the knowledge of healthcare professionals (HCPs) caring for people with bleeding disorders, enhanced outreach initiatives, facilitated resource sharing, increased government support for bleeding disorders through advocacy initiatives, and strengthened patient organizations through capacity building. Established more than 30 years ago, the WFH Twinning Program has supported 286 partnerships across 129 countries.
Hemophilia Organization Twinning (HOT) strengthens patient organizations and promotes organizational development to enhance advocacy and support services for people living with bleeding disorders. The following are the three new HOT twinning partnerships launched this year:
Twins | Twinning objectives |
Guinée – Île-de-France (France)
|
|
Twins | Twinning objectives |
Botswana – Pacific Northwest (U.S.A)
|
|
Twins | Twinning objectives |
Cambodia – Australia
|
|
Hemophilia Treatment Centre (HTC) Twinning helps HCPs provide adequate diagnosis, treatment and care for people living with bleeding disorders. This year, the program welcomed four new HTC partnerships:
Twins | Twinning objectives |
Conakry (Guinea) – Paris (France)
|
|
Twins | Twinning objectives |
Sarajevo (Bosnia and Herzegovina) – Milan (Italy) Emerging partner: Hemophilia Treatment Centre Clinical Centre University of Sarajevo Established partner: Centre for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital |
|
Twins | Twinning objectives |
Purwokerto (Indonesia) – Utrecht (Netherlands)
| Increase awareness among general practitioner physicians and first line HCPs
|
Twins | Twinning objectives |
Karachi (Pakistan) – Geneva (Switzerland)
|
|
The WFH looks forward to supporting these new partnerships and collaborating effectively with them to have a positive impact on lives of people with bleeding disorders worldwide.
To find out more about the WFH Twinning Program, click here.
The WFH Twinning Program is supported by exclusive funding from Pfizer and Sanofi.










